A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM)

Samuel Kemp , Dirk-Jan Slebos (1) , Alan Kirk , Malgorzata Kornaszewska , Kris Carron , Lars Ek , Gustav Broman , Gunnar Hillerdal , Hervé Mal (2) , Christophe Pison (3, 4) , Amandine Briault (5) , Nicola Downer , Kaid Darwiche , Jagan Rao , Ralf-Harto Hübner , Christof Ruwwe-Glosenkamp , Valery Trosini-Desert (6) , Ralf Eberhardt , Felix Herth , Eric Derom , Thomas Mal , Pallav Shah , Justin Garner , Nick ten Hacken , Hazem Fallouh , Sylvie Leroy (7) , Charles Marquette

1 UMCG - University Medical Center Groningen [Groningen]
2 Service de pneumologie B
3 LBFA - Laboratory of Fundamental and Applied Bioenergetics = Laboratoire de bioénergétique fondamentale et appliquée
4 CHU - Centre Hospitalier Universitaire [Grenoble]
5 UL - Université de Lorraine
6 Département " R3S " - Service de Pneumologie et Réanimation Médicale [CHU Pitié-Salpêtrière]
7 LSD - Lithosphère, structure et dynamique

Single-center randomized controlled trials of the Zephyr endobronchial valve (EBV) treatment have demonstrated benefit in severe heterogeneous emphysema. This is the first multicenter study evaluating this treatment approach.

Domains: Life Sciences [q-bio]

Samuel Kemp, Dirk-Jan Slebos, Alan Kirk, Malgorzata Kornaszewska, Kris Carron, et al.. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). American Journal of Respiratory and Critical Care Medicine, 2017, 196 (12), pp.1535-1543. ⟨10.1164/rccm.201707-1327OC⟩. ⟨hal-01963139⟩